Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 36, 2012, Pages 14586-14591

  Beckman, Robert A ^a,b   Schemmann, Gunter S ^c,d   Yeang, Chen Hsiang ^a,e  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d World Water and Solar Technologies   (United States)

^e INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

Author keywords

Combinations; Evolution; Systems biology; Targeted therapy; Treatment strategy

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; VEMURAFENIB;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CELL HETEROGENEITY; CELL POPULATION; EPIGENETICS; GENETICS; GROWTH RATE; IN VIVO STUDY; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; NEOPLASM; PANCREAS CANCER; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; SIMULATION; TRANSLATIONAL RESEARCH; TUMOR GROWTH; TUMOR VOLUME;

COMPUTER SIMULATION; EPIGENESIS, GENETIC; EVOLUTION, MOLECULAR; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; NEOPLASMS; SYSTEMS BIOLOGY;

EID: 84865973305     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203559109     Document Type: Article

References (43)

1. Loeb LA, Springgate CF, Battula N (1974) Errors in DNA replication as a basis of malignant changes. Cancer Res 34:2311-2321.
2. Pleasance ED, et al. (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191-196.
3. Wood LD, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113. (Pubitemid 350134889)
4. Parsons DW, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
5. Beckman RA (2010) Efficiency of carcinogenesis: Is the mutator phenotype inevitable? Semin Cancer Biol 20:340-352.
6. Beckman RA, Loeb LA (2006) Efficiency of carcinogenesis with and without a mutator mutation. Proc Natl Acad Sci USA 103:14140-14145. (Pubitemid 44452993)
7. Beckman RA (2009) Mutator mutations enhance tumorigenic efficiency across fitness landscapes. PLoS ONE 4:e5860.
8. Zhang J, et al. (2012) A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481:329-334.
9. Loeb LA, Bielas JH, Beckman RA (2008) Cancers exhibit a mutator phenotype: Clinical implications. Cancer Res 68:3551-3557, discussion 3557.
10. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767.
11. Gerlinger M, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892.
12. Yachida S, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-1117.
13. Klein CA, Hölzel D (2006) Systemic cancer progression and tumor dormancy: Mathematical models meet single cell genomics. Cell Cycle 5:1788-1798.
14. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E (1996) Genetic divergence in the clonal evolution of breast cancer. Cancer Res 56:1493-1497. (Pubitemid 26104008)
15. Shah SP, et al. (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461:809-813.
16. Mullighan CG, et al. (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322:1377-1380. (Pubitemid 352775249)
17. Anderson K, et al. (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469:356-361.
18. Notta F, et al. (2011) Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469:362-367.
19. Fox EJ, Salk JJ, Loeb LA (2009) Cancer genome sequencing - An interim analysis. Cancer Res 69:4948-4950.
20. Beckman RA, Clark J, Chen C (2011) Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov 10:735-748.
21. Longo DL (2012) Tumor heterogeneity and personalized medicine. N Engl J Med 366:956-957.
22. Maheswaran S, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366-377.
23. Wang S, et al. (2010) Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 16:1324-1330.
24. Orlova A, et al. (2007) Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67:2178-2186. (Pubitemid 46424237)
25. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792. (Pubitemid 40271173)
26. Turke AB, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77-88.
27. Riely GJ, et al. (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5155. (Pubitemid 47502083)
28. Lovly CM, Pao W (2012) Escaping ALK inhibition: Mechanisms of and strategies to overcome resistance. Sci Transl Med 4:120ps2.
29. Katayama R, et al. (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4:120ra17.
30. Bradeen HA, et al. (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N- ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 108:2332-2338. (Pubitemid 44497517)
31. Shah NP, et al. (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117:2562-2569. (Pubitemid 47494357)
32. Prahallad A, et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100-103.
33. Solit DB, Jänne PA (2012) Translational medicine: Primed for resistance. Nature 483:44-45.
34. Chandarlapaty S, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19(1):58-71.
35. Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733. (Pubitemid 10138923)
36. Norton L, Simon R (1976) Tumor size, sensitivity to therapy and the design of treatment protocols. Cancer Treat Rep 61:1307-1317. (Pubitemid 8204100)
37. Beckman RA, Loeb LA (2005) Negative clonal selection in tumor evolution. Genetics 171:2123-2131.
38. Shah SP, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395-399.
39. Haeno H, et al. (2012) Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148:362-375.
40. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607.
41. Heiser LM, et al. (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 109:2724-2729.
42. Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT (2011) A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 7(2):92-100.
43. Dutta PK (2005) Strategies and Games: Theory and Practice (MIT Press, Cambridge, MA).